Michael Paglia has over 16 years of experience building, leading and motivating process development and manufacturing teams to support clinical programs from early development to late-stage clinical trials.  He is responsible for GMP manufacturing operations and CMC regulatory strategy for the development of AlloVir’s allogeneic T cell therapies.

Previously, Michael was the Vice President of CMC Operations at Oncorus and Program Lead for the development of a next-generation oncolytic immunotherapy platform. Prior to Oncorus, he was the Sr. Director of Technical Operations and Head of Cellular Process Development and Manufacturing Operations at bluebird bio. During his tenure there, he was responsible for establishing internal and external cellular process development and analytics, cGMP manufacturing operations, CMC regulatory strategy, cellular procurement, and process characterization and validation activities for lentiviral vector-based autologous hematopoietic stem cell and CAR T cell programs.

Michael has a B.S. in Biology from Providence College and an M.S. in Science, Biochemistry and Cell Biology from the University of New Hampshire.